Cargando…

Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing

Somatic mutations in KRAS, NRAS, and BRAF genes are related to resistance to anti-EGFR antibodies in colorectal cancer. We have established an extended RAS and BRAF mutation assay using a next-generation sequencer to analyze these mutations. Multiplexed deep sequencing was performed to detect somati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakai, Kazuko, Tsurutani, Junji, Yamanaka, Takeharu, Yoneshige, Azusa, Ito, Akihiko, Togashi, Yosuke, De Velasco, Marco A., Terashima, Masato, Fujita, Yoshihiko, Tomida, Shuta, Tamura, Takao, Nakagawa, Kazuhiko, Nishio, Kazuto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425536/ https://www.ncbi.nlm.nih.gov/pubmed/25954997 http://dx.doi.org/10.1371/journal.pone.0121891

Ejemplares similares

Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer
por: Sakai, Kazuko, et al.
Publicado: (2015)

KIAA1199 interacts with glycogen phosphorylase kinase β-subunit (PHKB) to promote glycogen breakdown and cancer cell survival
por: Terashima, Masato, et al.
Publicado: (2014)

Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines
por: Terashima, Masato, et al.
Publicado: (2014)

Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition
por: KOGITA, AKIHIRO, et al.
Publicado: (2014)

Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer
por: Togashi, Yosuke, et al.
Publicado: (2014)

HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
por: Sakai, Hitomi, et al.
Publicado: (2018)

MEK inhibitors against MET-amplified non-small cell lung cancer
por: Chiba, Masato, et al.
Publicado: (2016)

Performance of Idylla(™) RAS-BRAF mutation test for formalin-fixed paraffin-embedded tissues of colorectal cancer
por: Makutani, Yusuke, et al.
Publicado: (2022)

Clinical and immune profiling for cancer of unknown primary site
por: Haratani, Koji, et al.
Publicado: (2019)

Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer
por: Watanabe, Satomi, et al.
Publicado: (2018)

Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study)
por: Matsuoka, Hiromichi, et al.
Publicado: (2017)

FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib
por: Hibi, Masaaki, et al.
Publicado: (2016)

Performance of Oncomine Fusion Transcript kit for formalin‐fixed, paraffin‐embedded lung cancer specimens
por: Sakai, Kazuko, et al.
Publicado: (2019)

HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer
por: Takegawa, Naoki, et al.
Publicado: (2015)

Expectation of a Decrease in Pain Affects the Prognosis of Pain in Cancer Patients: a Prospective Cohort Study of Response to Morphine
por: Matsuoka, Hiromichi, et al.
Publicado: (2017)

Incidence of carnitine deficiency in patients with cancer pain: A pilot study
por: Sakai, Kiyohiro, et al.
Publicado: (2017)

Successful long-term treatment of non–small cell lung cancer positive for RET rearrangement with pemetrexed
por: Takeda, Masayuki, et al.
Publicado: (2019)

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
por: Banno, Eri, et al.
Publicado: (2016)

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A
por: Chiba, Masato, et al.
Publicado: (2017)

Multiple regulatory mechanisms of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF gene promoter
por: SAKAI, KAZUKO, et al.
Publicado: (2015)

Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions
por: Sakai, Kazuko, et al.
Publicado: (2014)

Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence
por: Togashi, Yosuke, et al.
Publicado: (2014)

Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer
por: Suda, Kenichi, et al.
Publicado: (2015)

New Era for Next-Generation Sequencing in Japan
por: Takeda, Masayuki, et al.
Publicado: (2019)

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report
por: Takakura, Toshiaki, et al.
Publicado: (2023)

The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC
por: Kanemura, Hiroaki, et al.
Publicado: (2022)

Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production
por: Togashi, Yosuke, et al.
Publicado: (2013)

Collateral Chemoresistance to Anti-Microtubule Agents in a Lung Cancer Cell Line with Acquired Resistance to Erlotinib
por: Mizuuchi, Hiroshi, et al.
Publicado: (2015)

Melanoma Transition Is Frequently Accompanied by a Loss of Cytoglobin Expression in Melanocytes: A Novel Expression Site of Cytoglobin
por: Fujita, Yoshihiko, et al.
Publicado: (2014)

A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing
por: Sakai, Kazuko, et al.
Publicado: (2019)

Cell Adhesion Molecule 1 Contributes to Cell Survival in Crowded Epithelial Monolayers
por: Hagiyama, Man, et al.
Publicado: (2020)

Ciliated muconodular papillary tumors of the lung with KRAS/BRAF/AKT1 mutation
por: Udo, Emiko, et al.
Publicado: (2017)

Transcriptome Profiling and Metagenomic Analysis Help to Elucidate Interactions in an Inflammation-Associated Cancer Mouse Model
por: Sakai, Kazuko, et al.
Publicado: (2021)

A case of ALK-rearranged non–small cell lung cancer that responded to ceritinib after development of resistance to alectinib
por: Makuuchi, Yosuke, et al.
Publicado: (2018)

Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study)
por: Nishio, Kazuto, et al.
Publicado: (2023)

Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
por: Hirokawa, Esuteru, et al.
Publicado: (2021)

The intracellular domain of cell adhesion molecule 1 is present in emphysematous lungs and induces lung epithelial cell apoptosis
por: Hagiyama, Man, et al.
Publicado: (2015)

Progression of Pulmonary Emphysema and Continued Increase in Ectodomain Shedding of Cell Adhesion Molecule 1 After Cessation of Cigarette Smoke Exposure in Mice
por: Ri, Aritoshi, et al.
Publicado: (2018)

Pathogenic Actions of Cell Adhesion Molecule 1 in Pulmonary Emphysema and Atopic Dermatitis
por: Yoneshige, Azusa, et al.
Publicado: (2015)

Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples
por: Ishii, Hidenobu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qodqimco6mmct6ihd14pdtt8js